Real-World study reveals treatment persistence in lung fibrosis patients
NCT ID NCT06485635
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This completed study looked at over 10,000 people in France who were prescribed antifibrotic drugs for idiopathic pulmonary fibrosis (a serious lung disease). The goal was to see how many patients continued their treatment for up to 30 months and what factors might cause them to stop. By analyzing real-world data, researchers hope to find ways to improve long-term treatment adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinityx
Boulogne-Billancourt, 92100, France
Conditions
Explore the condition pages connected to this study.